[Dr.Vad]

Уважаемый Владимир!

CB - это каннабиноидные рецепторы; если будет интересным то приведу тезисы и фрагмент недавней статьи:

J Pharmacol Exp Ther. 2004 Nov 3;

CANNABINOID CB1 ANTAGONISTS AS PROMISING NEW MEDICATIONS FOR DRUG DEPENDENCE.

Le Foll B, Goldberg SR.

NIDA.

This review examines the development of cannabinoid CB1 receptor antagonists as a new class of therapeutic agents for drug addiction. Abused drugs (alcohol, opiates, Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and psychostimulants, including nicotine) elicit a variety of chronically relapsing disorders by interacting with endogenous neural pathways in the brain. In particular, they share the common property of activating mesolimbic dopamine brain reward systems and virtually all abused drugs elevate dopamine levels in the nucleus accumbens. Cannabinoid CB1 receptors are expressed in this brain reward circuit and modulate the dopamine-releasing effects of Delta(9)-THC and nicotine. Rimonabant (SR141716), a CB1 receptor antagonist, blocks both the dopamine-releasing and the discriminative and rewarding effects of Delta(9)-THC in animals. Blockade of CB1 receptor activity by genetic invalidation also decreases rewarding effects of opiates and alcohol in animals. Although CB1 receptor blockade is generally ineffective in reducing the self-administration of cocaine in rodents and primates, it reduces the reinstatement of extinguished cocaine-seeking behavior produced by cocaine-associated conditioned stimuli and cocaine priming injections. Similarly, CB1 receptor blockade is effective in reducing nicotine-seeking behavior induced by re-exposure to nicotine-associated stimuli. Some of these findings have been recently validated in humans. In clinical trials, Rimonabant blocks the subjective effects of Delta(9)-THC in humans and prevents relapse to smoking in ex-smokers. Findings from both clinical and preclinical studies suggest that ligands blocking CB1 receptors offer a novel approach for patients suffering from drug dependence that may be efficacious across different classes of abused drugs.


Two forms of cannabinoid receptors, CB1 and CB2, have been cloned (Matsuda et al., 1990; Gerard et al., 1991; Munro et al., 1993) . The CB1 receptor and its splice variant the CB1A receptor are predominantly found in the brain, with the highest density in the hippocampus, cerebellum, cortex and striatum, whereas CB2 receptors are located peripherally, principally associated with the immune system (Howlett et al., 2002). New data suggest the existence of an additional cannabinoid receptor (non-CB1/non-CB2) (see (Wilson and Nicoll, 2002). ∆9-THC may produce its effects by duplicating the effects of natural ligands for CB1 receptors (anandamide, 2-arachidonylglycerol and, perhaps, noladin ether), which have a shorter duration of action than synthetic or plant-derived cannabinoids and are implicated in various nervous system functions such as reward, memory, cognition and pain perception (Wilson and Nicoll, 2002).